Singapore, Sept. 22 -- To further enhance Taiwan's role in global clinical research and innovative drug development, accelerate the advancement of cutting-edge medical technologies, and improve patient access to innovative treatments, National Taiwan University Hospital and Johnson & Johnson Taiwan have formally signed a Memorandum of Understanding (MoU).

Through Johnson & Johnson Innovative Medicine's global R&D network, the two parties will deepen collaboration in areas such as cancer, immune-mediated diseases, and innovative medical technologies. The two parties have recently collaborated on several international scientific publications in oncology.

This MoU aims to establish a longer-term cooperation framework, beginning with innova...